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The Impact of Exercise, Lifestyle, and Clinical Factors on 
Perceived Cognitive Function in Patients with Rheumatoid 
Arthritis: Results from a Prospective Cohort Study
Nancy A. Shadick,1  Patricia Katz,2  Christine I. Iannaccone,1 Gabriela Maica,1 Jonathan Coblyn,1  
Michael E. Weinblatt,1 and Jing Cui1
Objective. Lifestyle factors, such as inactivity and obesity, contribute to cognitive decline in the general popu-
lation, but little is known about how these factors may affect individuals with a chronic inflammatory condition such 
as rheumatoid arthritis (RA). We studied the clinical and functional risk factors related to a worsening of perceived 
cognitive function in patients with RA.
Methods. We collected clinical and functional questionnaire data over 10 years in a prospective RA cohort in-
cluding yearly self-reported memory, concentration, and word-finding difficulties graded from “never” to “often.” 
Generalized estimating equation models examined the role of exercise (defined as those meeting the Department of 
Health and Human Services physical activity guidelines of 75 minutes of vigorous or 150 minutes of moderate aero-
bic activity per week), body mass index (BMI), sleep, depression (Mental Health Index-Depression), Disease Activity 
Score (DAS)28–c-reactive protein (CRP)3 score, disease-modifying antirheumatic drug, and corticosteroid use from 
the previous year as predictors of cognitive complaints that progressed to “often” compared with the previous year 
(the first year (Ti) progressed to “often” 1 year later (Ti+1)).
Results. Of 1219 RA subjects, 127 (10.4%) described either poor memory, concentration, or word-finding difficul-
ties as affecting them “often” at study entry. RA patients (n = 1092, mean age = 56.5 years, 82% female, 58% college 
educated) were less likely to report word-finding difficulties, poor memory, and concentration as “often” if they were 
physically active (p = 0.0001, P = 0.01, P < 0.0001, respectively). Female RA patients developed more concentration 
complaints compared with males (P = 0.03); patients taking an anti–tumor necrosis factor therapy were less likely to 
complain of poor memory (P = 0.01). Sleep, BMI, fatigue, depression, DAS28-CRP3, methotrexate, and corticoster-
oid use were not independently associated with a worsening of any cognitive complaints.
Conclusion. RA patients who are physically active are less likely to report cognitive difficulties. Our study sug-
gests potential modifiable risk factors for the prevention of cognitive dysfunction in RA.
INTRODUCTION
Individuals with inflammatory diseases such as rheumatoid 
arthritis (RA) have an increased prevalence of cognitive impair-
ment, and recent articles suggest an increase in rates of Alzheim-
er’s dementia (1–5). Measurable cognitive impairment is estimated 
to occur in 30% to 71% of patients with RA in several studies (1,6); 
other studies have demonstrated an association between cogni-
tion and disease activity (7). A recent review of cognitive impair-
ment in RA (5) demonstrated that RA patients underperformed 
on cognitive function tests compared with controls especially in 
areas of memory, attention, and verbal function. This impairment 
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may limit self-management of the disease and worsen functional 
outcomes (8). However, screening for cognitive impairment with 
neuropsychological testing presents challenges as its administra-
tion is costly, time intensive, and requires specialized personnel to 
administer and interpret tests.
In healthy cohorts, investigations of preclinical Alzheimer’s 
type dementia have suggested that subjective cognitive com-
plaints may precede abnormalities detected on neuropsycho-
logical testing (9,10). However, in RA, cognitive impairment can 
co-occur with markers of psychological distress (11), and self- 
reported cognitive dysfunction can be influenced by symptoms 
of depression and fatigue (12). Appreciating the role that clinical 
and psychological factors play in the perception of cognition is 
important because cognitive complaints are clinically meaningful 
to patients and may portend cognitive decline.
Potentially modifiable lifestyle factors such as inactivity and 
obesity are risk factors for cognitive decline in the general pop-
ulation (13,14). However, little is known about how these factors 
may contribute in the setting of a chronic inflammatory condition 
such as RA, although one study in systemic lupus erythemato-
sus reported similar risk (15). In the present analysis, we stud-
ied RA patients followed since 2003 who reported yearly on their 
perceived cognition to better understand the risk factors for this 
outcome.
PATIENTS AND METHODS
Study design and patient population. The Brigham and 
Women’s Arthritis Rheumatoid Arthritis Sequential Study (BRASS) 
registry is a large prospective, observational cohort at the Brigham 
and Women’s Arthritis Center in Boston, Massachusetts. Enroll-
ment for the registry began in March 2003 and is ongoing. Patients 
(ages 18 or older) with either new onset or established RA disease 
were recruited from the practices of rheumatologists. All diag-
noses of RA were then verified according to either the American 
College of Rheumatology (ACR) criteria (16) or were the clinical 
opinion of a rheumatologist. Each patient signed an informed con-
sent form that was obtained according to the Declaration of Hel-
sinki and approved by the Partners Institutional Review Board at 
Brigham and Women’s Hospital. Annual visits collected updated 
information on demographics, disease activity, medication use, 
comorbidities, psychosocial variables, and functional status. Addi-
tionally, serum was collected yearly. Details and information related 
to participation and the protocol in the BRASS registry has been 
reported elsewhere (17). In this analysis, BRASS participants were 
followed for up to 10 years. Individuals who completed at least two 
consecutive annual assessments were studied.
Measures. Patients’ self-assessment of cognition. Subjects 
in the BRASS registry reported their cognitive complaints at their 
yearly visits. Patients were asked “Do you have any of the follow-
ing symptoms NOW?” in the categories of poor memory, poor 
concentration, and word-finding difficulties. Each question was 
rated as “not at all,” “sometimes,” or “often.” We defined worsen-
ing of a cognitive complaint if the description of difficulty changed 
from either “not at all” or “sometimes” to “often” for any of the 
three questions.
Other patient-reported measures. Patients were asked to 
complete an annual questionnaire that inquired about their age, 
sex, education, ethnicity, and disease duration. Education was 
grouped into graduated high school, graduated college, and 
completed graduate school or higher. All other variables were 
analyzed as continuous variables and were updated yearly.
Each of the following measures was assessed at each annual 
visit. Sleep was rated using an item from the Multidimensional 
Health Assessment Questionnaire (MDHAQ): “Over the past week 
were you able to get a good night’s sleep?” (range 0-3) (18). A 
visual analog scale from the MDHAQ scale was used to rate fatigue 
severity on a scale of 0 (no fatigue) to 100 (maximum fatigue) over 
the previous week. The five-item Mental Health Index-5 (MHI-5) 
was administered and scored to obtain the MHI-D depression sub-
scale; higher scores indicate worse depressive symptoms (19,20).
Physical activity was measured with the Nurse’s Health Study 
II physical activity scale, which is a self-reported scale assess-
ing the frequency, duration, and intensity of physical activity in 
a variety of different modes of exercise in the preceding week 
(21). Respondents were categorized active or inactive, based on 
whether they met the 2008 US Department of Health and Human 
Services (HHS) physical activity guideline (150 minutes or more 
of moderate intensity activity or 75 minutes or more of vigorous 
activity per week) (22).
Other variables. Disease activity was measured with the 
Disease Activity Score-28 (DAS28)–c-reactive protein 3 (CRP3) 
(23), a composite score consisting of a physician-reported 28 
joint count and CRP lab values. Subjects were categorized as 
having cardiovascular disease if they had a myocardial infarc-
tion, angioplasty, cardiac catheterization, coronary artery bypass 
grafting, congestive heart failure or stroke. Body mass index 
(BMI) and current medications were recorded at each study visit.
Statistical analyses. Demographic and clinical variables 
were tabulated for all patients with at least two consecutive yearly 
data points. We also tabulated the percentages of BRASS patients 
that had answered each question at each time point. To evaluate 
whether the frequency of cognitive complaints described as “often” 
increased over time, we ran a mixed effects logistic regression for 
trend for each question using the GLIMMIX procedure (Figure 1). 
We then ran an analysis for the main binary outcome variable, 
which was defined as a change from a description of “not at all” or 
“sometimes” to “often” for each of the cognitive complaints between 
consequent questionnaires, to identify predictors of new cognitive 
complaints. Covariates for this analysis came from the prior study 
visit and included age, gender, education, BMI, medication use 
(methotrexate, anti–tumor necrosis factor (TNF), corticosteroid use), 
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DAS28-CRP3 score, sleep, fatigue, MHI-D depression score, and 
also required that physical activity guidelines were met, adjusted for 
days between visits. Generalized estimating equation (GEE) model 
analyses to identify predictors of developing a cognitive complaint 
were conducted using the GENMOD procedure for each of the 
three questions. Because subjects had multiple visits, they were 
able to make more than one transition to “often.” Study dropouts 
had data through their last visit included in the analyses. Any missing 
data remained as missing and was not imputed. A value of P < 0.05 
was considered significant. All analyses were performed using SAS 
software, version 9.4 (SAS Institute).
RESULTS
At study entry, of the 1219 members in the study, 127 (10.4%) 
described either poor memory, poor concentration, or word- 
finding difficulties as occurring “often” and were excluded from 
further analysis. Among this group, 36 of 127 (28%) complained 
of all three symptoms. Nineteen (15%) complained of word-finding 
difficulties and poor memory “often,” 11 (9%) complained of poor 
memory and concentration difficulties, and 7 complained “often” 
of word-finding difficulties and concentration difficulties.
Table  1 delineates the clinical characteristics and demo-
graphics of the members of the BRASS cohort that contributed 
data to the analysis at the time of study entry (n = 1092). The 
cohort had a mean age of 56.5 years, they were mostly female, 
and more than half had a college degree. The study cohort’s mean 
follow-up duration was 5.4 years (range: 1-10.9). The great major-
ity of subjects were Caucasian. They had long-standing disease 
with a mean disease duration of 12.8 years (±11.9). Their DAS28-
CRP3 scores averaged 3.6, indicating moderate disease activity. 
Approximately 28% currently used corticosteroids and one-third 
(37.7%) were using anti-TNF therapy at study entry. Thirteen per-
cent (13%) of the cohort met the US Department of HHS guide-
lines for exercise, and 8.1% entered the cohort with a history of 
cardiovascular disease.
By the end of the 10-year study period, 11.4% complained of 
at least one symptom as occurring “often” compared with 10.4% 
at baseline. The percentage of study subjects complaining that 
they “often” had the individual symptom complaint at each study 
visit is illustrated in Figure 1. Although trend lines demonstrated an 
increase in the frequency of all of the cognitive complaints, only 
memory complaints increased significantly over time, from 6.3% 
to 8.8% by study end (P = 0.047).
Table 2 demonstrates the GEE analysis of predictors of per-
ceived cognitive complaints described as occurring “often.” RA 
patients who took TNF inhibitors and those who were active were 
less likely to report a worsening of memory (odds ratio [OR] (con-
Figure 1. Percentage of study cohort members who each reported 
cognitive complaint of “often” at each study visit (n = 1219). Number 
of subjects in each study visit (months): 0, n = 1219; 12, n = 1122; 
24, n = 926; 36, n = 817; 48, n = 723; 60, n = 598; 72, n = 404; 84, 
n = 350; 96, n = 326; 108, n = 279; 120, n = 258. P value reflects 
the mixed effects logistic regression trend for each question using 
the GLIMMIX procedure.
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Table 1. Demographics and clinical characteristics of the BRASS 
cohort at study entry (N = 1092)
Variable Numerical Values
Age, years (mean, SD) 56.5 (13.7)
Gender (female) (N, %) 894 (81.9)
Education (college or more) (N, %) 632 (58.1)
Race (white) (N, %) 1006 (92.8)
Corticosteroid use (N, %) 306 (28.0)
Anti-TNF use (N, %) 411 (37.7)
Methotrexate use (N, %) 562 (51.5)
Physically active (N,%) 138 (12.7)
DAS28-CRP3 (mean, SD) 3.6 (1.6)
Depression score (MHI-D) (3-15)a 
(mean, SD)
12.5 (2.1)
Fatigue (VAS) (0-100)a (mean, SD) 39.1 (28.7)
Sleep difficulties (MDHAQ) (0-3)a 
(mean, SD)
0.8 (0.8)
Cardiovascular disease (N, %) 99 (8.1)
Disease duration, y (mean, SD) 12.8 (11.9) 
BMI (mean, SD) 26.8 (5.7)
Abbreviation: BMI, body mass index; MDHAQ, Multidimensional 
Health Assessment Questionnaire; MHI-D, Mental Health Index- 
Depression; TNF, tumor necrosis factor; VAS, visual analog scale.
aHigher score indicates worse value.
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fidence interval [CI]), 0.69 (0.53,0.90) P = 0.01; 0.83 (0.72,0.96); 
P = 0.01, respectively). Those who were active were also less likely 
to report word-finding difficulties occurring “often” (OR [CI], 0.45 
[0.30,0.67], P = 0.0001). No other factor predicted an increase in 
reports of word-finding difficulties. Worsened concentration was 
more likely to be reported as “often” 1 year later among those RA 
patients who were female (OR [CI],4.88 [1.13,21.12], P = 0.03), 
had a higher DAS28-CRP3 score (OR [CI], 1.07 [0.99,1.17], 
P = 0.09), or those who were not active (OR [CI], 0.82 [0.77,0.87], 
P < 0.0001).
We evaluated whether individuals who dropped out of our 
study (approximately 5% per year) were more likely to have an 
increase in cognitive complaints prior to drop out. We evaluated 
the frequency of each of the cognitive complaints at a patient’s 
last visit prior to dropping out and compared it with those who 
remained in the study. We did not find that the subjects who 
dropped had more cognitive complaints of poor memory, 
word-finding difficulties, or trouble with concentration at multiple 
time points (data not shown).
DISCUSSION
In this study, we examined how exercise and lifestyle fac-
tors interacted with clinical factors as predictors of cognitive 
complaints in three domains: memory, concentration, and word 
retrieval difficulties. In middle-aged RA patients followed since 
2003 who reported yearly on their perceived cognition, we found 
that meeting guidelines for physical activity protected against the 
development of frequent complaints of word finding, memory, and 
concentration difficulties. Taking anti-TNF therapy was also pro-
tective for the development of worsening memory. Additionally, 
female gender predicted an increase in concentration difficulties, 
indicating the complex role that clinical, demographic, and psy-
chosocial factors can play in how RA patients assess their cogni-
tive function in the setting of chronic inflammation.
Meeting physical activity guidelines protected against an 
increase in all three self-reported cognitive difficulties. The find-
ing that regular physical activity is beneficial for cognitive function 
and reduces longitudinal decline in cognition and risk of depres-
sion has been studied widely in healthy older adults (13,24–26). 
Aerobic exercise has also recently been shown to be effective in 
improving cognition and increasing cortical thickness in younger 
healthy individuals (27). In systemic lupus erythematosus, physical 
inactivity and obesity were associated with impairment in cog-
nitive function also adjusting for demographics, disease activity, 
and depression (15). Regular physical activity has been shown to 
decrease levels of inflammatory markers such as CRP, interleukin 
(IL)-6, and TNF-alpha in healthy individuals (28,29), and IL-6 and 
CRP have been shown to increase dementia incidence in mid-life 
(30). This may explain, in part, how RA inflammation may con-
tribute to worsened cognition and exercise may ameliorate this 
effect. In a recent systematic review of cognitive impairment in 
RA, several studies report a relationship with disease activity and 
reduced performance on cognitive function tests (5). In a study by 
Lee et al (7), cognitive function in RA was associated with disease 
activity rather than carotid atherosclerotic changes. Additionally, 
Chou et al (3) demonstrated an increased risk of Alzheimer’s dis-
ease in the RA population that was lowered in those exposed to 
Table 2. Generalized estimate equations multivariate models of demographic and clinical factors associated with worsened cognitive function 
(N = 1092)a
Variable
Poor Memory Word-Finding Difficulty Poor Concentration
95% CI 95% CI 95% CI
OR lower upper P value OR lower upper P value OR lower upper P value
Physically activeb 0.83 0.72 0.96 0.01* 0.45 0.30 0.67 0.0001* 0.82 0.77 0.87 <0.0001*
Anti-TNF use 0.69 0.53 0.90 0.01* 1.14 0.71 1.83 0.58 0.75 0.54 1.06 0.10
DAS28-CRP3 1.07 0.98 1.17 0.14 1.02 0.91 1.13 0.78 1.07 0.99 1.17 0.09
Gender (female) 2.67 0.80 8.90 0.11 1.21 0.46 3.22 0.70 4.88 1.13 21.12 0.03*
Depression score 
(MHI-D)
0.99 0.90 1.09 0.82 1.05 0.97 1.14 0.22 0.97 0.92 1.02 0.24
Methotrexate use 0.83 0.60 1.16 0.28 0.78 0.51 1.19 0.25 1.06 0.77 1.45 0.72
Corticosteroid use 0.92 0.62 1.37 0.69 0.99 0.62 1.56 0.95 1.22 0.96 1.54 0.11
BMI 1.00 0.96 1.04 0.82 1.00 0.96 1.03 0.92 0.98 0.93 1.03 0.46
Education (college 
degree or more)
0.83 0.44 1.55 0.55 0.83 0.42 1.66 0.60 0.84 0.41 1.72 0.63
Sleep difficulties 
(MDHAQ)
1.09 0.82 1.45 0.54 0.99 0.77 1.26 0.92 1.09 0.92 1.28 0.31
Fatigue (VAS) 1.00 0.99 1.01 0.70 1.00 1.00 1.01 0.70 1.00 0.99 1.00 0.36
Age, y 1.00 0.98 1.02 1.00 1.00 0.97 1.02 0.78 0.99 0.97 1.01 0.48
Abbreviation: CI, confidence interval; DAS28-CRP, Disease Activity Score 28 joints–c-reactive protein; MDHAQ, Multidimensional Health Assess-
ment Questionnaire; MHI-D, Mental Health Index-Depression; OR, odds ratio; TNF, tumor necrosis factor; VAS, visual analog scale.
aAdjusted for time (days) between questionnaires. bMeeting the US Department of Health and Human Services recommendation for physical 
activity.
* P < 0.05. 
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etanercept. In our study, higher disease activity showed a trend 
toward reports of poor concentration. Anti-TNF use was protec-
tive against a worsening of memory complaints and showed a 
trend toward protection against concentration difficulties, sug-
gesting that inflammation may also play a role in perceived cogni-
tive function. In RA patients, there are many benefits to exercise. 
Physical activity has been shown to reduce vascular stiffness and 
increase small, high-density lipoprotein particle concentration (31), 
improve cardiovascular risk by improving endothelial function (32), 
reduce fatigue, pain, and symptoms of depression (33,34) as well 
as improve disease activity and reduce bone loss (35). All of these 
effects could contribute to reports of improved cognition in our 
participants. Of note, neither corticosteroids nor methotrexate use 
affected cognitive complaints in this study.
An increase in symptoms of depression influencing a report 
of worsened perceived cognition has been noted in other studies 
of individuals with chronic disease and in healthy subjects (36). 
Studies in patients with multiple sclerosis and cancer corrobo-
rated that depressive symptoms affect a patients’ report of cog-
nitive difficulties (36–39). In RA, Shin et al found that higher levels 
of depression and fatigue were associated with perceived cogni-
tive dysfunction in 120 well-characterized patients with RA (12). 
However, we found that after adjusting for multiple other known 
risk factors for cognitive function, higher depression scores did 
not affect the development of reports of frequent concentration, 
memory, or word-finding difficulties. Our repeated measures of 
fatigue, sleep, BMI—independent of depression and other fac-
tors—did not influence cognitive complaints. Differences in study 
design, inclusion of disease severity, and inclusion of other clinical 
and demographic factors may account for these differences.
Patients with RA need adequate cognitive capacity, especially 
given their complex medication management and intermittent dif-
ficulties in performance of activities of daily living. Understanding 
what factors account for cognitive complaints is helpful in choos-
ing who may need neuropsychological testing or brain imaging to 
document impairment. Several studies of healthy subjects report 
that subjective cognitive complaints may indicate early cognitive 
impairment not detectable on neurocognitive testing (9,40). Oth-
ers suggest that subjective cognitive complaints in healthy subjects 
relate more to depression (41,42). Amariglio et al reported that even 
when the effects of depression are considered, there is a relation-
ship between subjective cognitive complaints and objective cogni-
tive impairment (43) and that subjective cognitive complaints were 
related to amyloid burden measure by positron emission tomogra-
phy scanning (9). However, the study of persons with RA by Shin 
et al (12) revealed a gap between self-reported cognitive complaints 
and objective cognitive impairment that was more influenced by 
depression and fatigue. Although we did not do neuropsychological 
assessments in our study to determine impairment, the report of 
frequent memory, word-finding difficulties, or concentration difficul-
ties was alarming to our patients and were presented to their doc-
tors as a frequent complaint. Understanding how other risk factors 
for cognitive impairment, such as education level, BMI, exercise, 
medication use, disease activity, and psychosocial factors, contrib-
ute to this self-assessed symptom is useful to a treating physician 
who may need to decide if further cognitive testing is necessary. If 
clinicians are interested in screening RA patients for early dementia 
and do not have the resources or time to perform neurocognitive 
testing, understanding the role that lifestyle and clinical factors play 
in the report of cognition difficulties is important.
Our study is of value in that it provides longitudinal data 
on the frequency of cognitive complaints in RA. There are few 
studies that document the prevalence of self-reported cognitive 
difficulties over time in patients with RA. In the study by Shin 
et al (12), the mean Perceived Deficits Questionnaire (PDQ) score 
(a questionnaire used in multiple sclerosis patients that reports 
how often respondents have difficulty with attention, memory, 
and planning) was 5.8 out of a possible 16 in a group of 120 
well-studied patients with RA. This indicated an overall average 
of difficulties categorized between “rarely” and “sometimes.” In 
another study of 114 patients with a variety of rheumatic dis-
eases including RA, up to 56% had at least one cognitive com-
plaint in those with and without fibromyalgia at one time point 
(44). In the current study, we documented over 10 years that a 
variety of symptom complaints occur in RA patients and that the 
frequency of memory difficulties increases over time. Although 
subjects in the study were highly educated and cognitively well 
enough to fill out our questionnaires, we also found that subjects 
who dropped out did not do so because they more likely had 
cognitive complaints. Having data on the frequency of cogni-
tive complaints in RA is useful and informative. It expands our 
understanding of the functional difficulties that patients with RA 
encounter every day.
Our study has several limitations. Although we are report-
ing data on patients’ perceived cognitive difficulties, we do not 
have neurocognitive testing as a comparison or gold standard 
of impairment and thus the relationship of perceived cognitive 
function to actual cognitive function is unclear. The risk factors 
we report for worsened cognitive complaints, therefore, may 
not directly link to dementia. However, the frequent complaints 
of the BRASS subjects appeared meaningful. Anecdotally, the 
BRASS patients who complained of frequent cognitive difficul-
ties felt that this affected the quality of their lives. Although it did 
not appear that subjects who dropped out had an increased 
frequency of cognitive complaints, suggesting that this may be 
a cause for attrition, a stable cohort study could have provided 
more accurate data on the prevalence of cognitive complaints 
over time. Having access to a parallel analysis of a normal 
control group would also clarify the comparative prevalence 
of these complaints. Future studies should examine the func-
tional implications of this increase in perceived cognitive diffi-
culty, its relationship to objective impairment, and whether this 
difficulty is related to other diminished RA outcomes. We did 
not screen participants for fibromyalgia, which is associated 
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with cognitive complaints. However, only 3 of the 127 who 
had cognitive complaints affecting them “often” at the study 
entry had a concurrent diagnosis of fibromyalgia, and only 15 
of the entire cohort of 1219 subjects carried a diagnosis of 
fibromyalgia.
Although we queried subjects on a three-point scale in the 
three cognitive domains previously reported as impaired in RA 
patients, our questions do not come from a validated question-
naire. We, therefore, do not have any data on validity, reliability, 
or sensitivity to change. Furthermore, although we chose the 
outcome transitioning to complaints described as “often” from 
either “never” or “sometimes,” these transitions are not equiva-
lent; and although an increase in memory complaints reported 
“often,” for example, from 6.3% to 8.8%, appears to be small, 
many more subjects (40%-48%) reported cognitive complaints 
that “sometimes” affected them. These complaints may also be 
clinically meaningful.
In summary, our study reported on the impact of exercise 
and other lifestyle and clinical factors on the development of 
frequent cognitive complaints in memory, concentration, and 
word retrieval domains. Clinical factors, such as anti-TNF 
use, reduced the likelihood of worsened memory dysfunc-
tion. Both lower disease activity and anti-TNF use showed 
trends toward fewer concentration difficulties. However, 
meeting the Department of HHS guidelines for exercise was 
the strongest protector against an increase in concentration, 
memory, and word retrieval difficulties. If perceived cogni-
tive difficulties precede cognitive decline in RA, our study 
suggests potential risk factors for intervention that could be 
tested in a randomized controlled trial. Future studies should 
investigate the functional sequelae of these cognitive com-
plaints, whether longitudinal follow-up of these individuals 
predicts an increase in cognitive impairment or dementia, 
and whether an increase in exercise may ward off these 
debilitating outcomes.
ACKNOWLEDGMENTS
We thank the dedicated rheumatoid arthritis participants 
and staff of the Brigham Rheumatoid Arthritis Sequential Study 
(BRASS) at Brigham and Women’s Hospital for their continued 
participation in this longitudinal research study.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it criti-
cally for important intellectual contact, and all authors approved the final 
version to be published. Dr. Shadick had full access to all of the data in 
the study and takes responsibility for the integrity of the data and the 
accuracy of the data analysis.
Study conception and design. Shadick, Weinblatt, Cui, Iannaccone, 
Maica, Katz,
Acquisition of data. Iannaccone, Coblyn, Maica, Weinblatt, Shadick.
Analysis and interpretation of data. Cui, Iannaccone, Katz, Coblyn, 
Weinblatt, Shadick.
REFERENCES
 1. Shin SY, Katz P, Wallhagen M, Julian L. Cognitive impairment in 
persons with rheumatoid arthritis. Arthritis Care Res (Hoboken) 
2012;64:1144–50.
 2. Wallin K, Solomon A, Kåreholt I, Tuomilehto J, Soininen H, Kivipelto 
M. Midlife rheumatoid arthritis increases the risk of cognitive impair-
ment two decades later: a population-based study. J Alzheimers Dis 
2012;31:669–76.
 3. Chou RC, Kane M, Ghimire S, Gautam S, Gui J. Treatment for 
rheumatoid arthritis and risk of Alzheimer's disease: a nested case- 
control analysis. CNS Drugs 2016;30:1111–20.
 4. Wotton CJ, Goldacre MJ. Associations between specific 
autoimmune diseases and subsequent dementia: retrospective 
record-linkage cohort study, UK. J Epidemiol Community Health 
2017;71:576–83.
 5. Meade T, Manolios N, Cumming SR, Conaghan PG, Katz P. Cogni-
tive impairment in rheumatoid arthritis: a systematic review. Arthritis 
Care Res (Hoboken) 2018;70:39–52.
 6. Appenzeller S, Bertolo MB, Costallat LT. Cognitive impairment in rheu-
matoid arthritis. Methods Find Exp Clin Pharmacol 2004;26:339–43.
 7. Lee JH, Kim GT, Kim YK, Lee SG. Cognitive function of patients with 
rheumatoid arthritis is associated with disease activity but not carotid 
atherosclerotic changes. Clin Exp Rheumatol 2018;36:856–61.
 8. Shin SY, Julian L, Katz P. The relationship between cognitive func-
tion and physical function in rheumatoid arthritis. J Rheumatol 
2013;40:236–43.
 9. Amariglio RE, Becker JA, Carmasin J, Wadsworth LP, Lorius N, 
Sullivan C, et al. Subjective cognitive complaints and amyloid 
burden in cognitively normal older individuals. Neuropsychologia 
2012;50:2880–6.
 10. Van Harten AC, Smits LL, Teunissen CE, Visser PJ, Koene T, 
Blankenstein MA, et al. Preclinical AD predicts decline in mem-
ory and executive functions in subjective complaints. Neurology 
2013;81:1409–16.
 11. Medina LD, Hirshberg L, Taylor MJ, Gilbert PE, Heaton RK. Rates 
of neuropsychological dysfunction in fibromyalgia and rheumatoid 
arthritis: an automated clinical rating approach. J Clin Rheumatol 
2019;25:252–7.
 12. Shin SY, Katz P, Julian L. Relationship between perceived cogni-
tive dysfunction and objective neuropsychological performance 
in persons with rheumatoid arthritis. Arthritis Care Res (Hoboken) 
2013;65:481–6.
 13. Middleton LE, Manini TM, Simonsick EM, Harris TB, Barnes DE, 
Tylavsky F, et al. Activity energy expenditure and incident cognitive 
impairment in older adults. Arch Intern Med 2011;171:1251–7.
 14. Cournot M, Marquié JC, Ansiau D, Martinaud C, Fonds H, Ferrières 
J, et al. Relation between body mass index and cognitive function in 
healthy middle-aged men and women. Neurology 2006;67:1208–14.
 15. Katz P, Julian L, Tonner MC, Yazdany J, Trupin L, Yelin E, et al. 
Physical activity, obesity, and cognitive impairment among women 
with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 
2012;64:502–10.
 16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper 
NS, et al. The American Rheumatism Association 1987 revised cri-
teria for the classification of rheumatoid arthritis. Arthritis Rheum 
1988;31:315–24.
 17. Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, 
et al. Using genetic and clinical data to understand response to dis-
ease-modifying anti-rheumatic drug therapy: data from the Brigham 
and Women's Hospital Rheumatoid Arthritis Sequential Study. 
Rheumatology (Oxford) 2011;50:40–6.
 18. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health 
Assessment Questionnaire (MDHAQ): assessment of advanced 
SHADICK ET AL 626       |
activities of daily living and psychological status in the patient-friendly 
health assessment questionnaire format. Arthritis Rheum 1999; 
42:2220–30.
 19. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health 
survey (SF-36). I. Conceptual framework and item selection. Med 
Care 1992;30:473–83.
 20. Cuijpers P, Smits N, Donker T, ten Have M, de Graaf R. Screen-
ing for mood and anxiety disorders with the five-item, the three-
item, and the two-item Mental Health Inventory. Psychiatry Res 
2009;168:250–5.
 21. Wolf AM, Hunter DJ, Colditz GA, Manson JE, Stampfer MJ, Corsano 
KA, et al. Reproducibility and validity of a self-administered physical 
activity questionnaire. Int J Epidemiol 1994;23:991–9.
 22. Office of Disease Prevention and Health Promotion. 2008 Physical 
Activity Guidelines for Americans. 2008. URL: https ://health.gov/
pagui delin es/2008/.
 23. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de 
Putte LB, van Riel PL. Modified disease activity scores that include 
twenty-eight-joint counts. Development and validation in a prospec-
tive longitudinal study of patients with rheumatoid arthritis. Arthritis 
Rheum 1995;38:44–8.
 24. Weuve J, Kang JH, Manson JE, Breteler MM, Ware JH, Grodstein 
F. Physical activity, including walking, and cognitive function in older 
women. JAMA 2004;292:1454–61.
 25. Angevaren M, Aufdemkampe G, Verhaar HJ, Aleman A, Vanhees L. 
Physical activity and enhanced fitness to improve cognitive function 
in older people without known cognitive impairment. Cochrane Da-
tabase Syst Rev 2008;CD005381.
 26. Harvey SB, Øverland S, Hatch SL, Wessely S, Mykletun A, Hotopf 
M. Exercise and the prevention of depression: results of the HUNT 
cohort study. Am J Psychiatry 2018;175:28–36.
 27. Stern Y, MacKay-Brandt A, Lee S, McKinley P, McIntyre K, Razlighi 
Q, et al. Effect of aerobic exercise on cognition in younger adults: a 
randomized clinical trial. Neurology 2019;92:e905–16.
 28. Colbert LH, Visser M, Simonsick EM, Tracy RP, Newman AB, 
Kritchevsky SB, et al. Physical activity, exercise, and inflammatory 
markers in older adults: findings from the Health, Aging and Body 
Composition Study. J Am Geriatr Soc 2004;52:1098–104.
 29. Reuben DB, Judd-Hamilton L, Harris TB, Seeman TE, MacArthur 
Studies of Successful Aging. The associations between physical activ-
ity and inflammatory markers in high-functioning older persons: MacAr-
thur Studies of Successful Aging. J Am Geriatr Soc 2003;51:1125–30.
 30. Singh-Manoux A, Dugravot A, Brunner E, Kumari M, Shipley M, 
Elbaz A, et al. Interleukin-6 and C-reactive protein as predictors of 
cognitive decline in late midlife. Neurology 2014;83:486–93.
 31. Byram KW, Oeser AM, Linton MF, Fazio S, Stein CM, Ormseth 
MJ. Exercise is associated with increased small HDL particle 
 concentration and decreased vascular stiffness in rheumatoid 
 arthritis. J Clin Rheumatol 2018;24:417–21.
 32. Metsios GS, Stavropoulos-Kalinoglou A, Sandoo A, van Zanten JJ, 
Toms TE, John H, et al. Vascular function and inflammation in rheu-
matoid arthritis: the role of physical activity. Open Cardiovasc Med J 
2010;4:89–96.
 33. Kelley GA, Kelley KS, Hootman JM. Effects of exercise on depres-
sion in adults with arthritis: a systematic review with meta-analysis of 
randomized controlled trials. Arthritis Res Ther 2015;17:21.
 34. Weinstein AA, Drinkard BM, Diao G, Furst G, Dale JK, Straus SE, 
et al. Exploratory analysis of the relationships between aerobic ca-
pacity and self-reported fatigue in patients with rheumatoid arthritis, 
polymyositis, and chronic fatigue syndrome. PM R 2009;1:620–8.
 35. Verhoeven F, Tordi N, Prati C, Demougeot C, Mougin F, Wendling 
D. Physical activity in patients with rheumatoid arthritis. Joint Bone 
Spine 2016;83:265–70.
 36. Singh-Manoux A, Dugravot A, Ankri J, Nabi H, Berr C, Goldberg M, 
et al. Subjective cognitive complaints and mortality: does the type 
of complaint matter? [research support]. J Psychiatr Res 2014;48: 
73–8.
 37. Cull A, Hay C, Love SB, Mackie M, Smets E, Stewart M. What do 
cancer patients mean when they complain of concentration and 
memory problems? [original article]. Br J Cancer 1996;74:1674–9.
 38. Julian L, Merluzzi NM, Mohr DC. The relationship among depres-
sion, subjective cognitive impairment, and neuropsychological per-
formance in multiple sclerosis. Mult Scler 2007;13:81–6.
 39. Middleton LS, Denney DR, Lynch SG, Parmenter B. The relationship 
between perceived and objective cognitive functioning in multiple 
sclerosis. Arch Clin Neuropsychol 2006;21:487–94.
 40. Reisberg B, Prichep L, Mosconi L, John ER, Glodzik-Sobanska L, 
Boksay I, et al. The pre-mild cognitive impairment, subjective cog-
nitive impairment stage of Alzheimer's disease. Alzheimers Dement 
2008;4 Suppl 1:S98–108.
 41. Smith GE, Petersen RC, Ivnik RJ, Malec JF, Tangalos EG. Sub-
jective memory complaints, psychological distress, and longitu-
dinal change in objective memory performance. Psychol Aging 
1996;11:272–9.
 42. Minett TS, Da Silva RV, Ortiz KZ, Bertolucci PH. Subjective memory 
complaints in an elderly sample: a cross-sectional study. Int J Geriatr 
Psychiatry 2008;23:49–54.
 43. Amariglio RE, Townsend MK, Grodstein F, Sperling RA, Rentz DM. 
Specific subjective memory complaints in older persons may indi-
cate poor cognitive function. J Am Geriatr Soc 2011;59:1612–7.
 44. Katz RS, Heard AR, Mills M, Leavitt F. The prevalence and clinical 
impact of reported cognitive difficulties (fibrofog) in patients with 
rheumatic disease with and without fibromyalgia. J Clin Rheumatol 
2004;10:53–8.
